Top MarketRank™ StocksTop MarketRank™NASDAQ:IRMD Iradimed (IRMD) Stock Price, News & Analysis $47.51 +0.26 (+0.55%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$46.56▼$47.7350-Day Range$42.03▼$47.9852-Week Range$36.12▼$50.85Volume49,102 shsAverage Volume50,869 shsMarket Capitalization$601.48 millionP/E Ratio33.70Dividend Yield1.26%Price Target$62.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Iradimed alerts: Email Address Iradimed MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside31.6% Upside$62.50 Price TargetShort InterestHealthy1.84% of Float Sold ShortDividend StrengthModerateBased on Four FactorsSustainability-0.85Upright™ Environmental ScoreNews Sentiment0.69Based on 5 Articles This WeekInsider TradingN/AProj. Earnings Growth21.28%From $1.41 to $1.71 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.98 out of 5 starsMedical Sector2nd out of 936 stocksSurgical & Medical Instruments Industry2nd out of 101 stocks 3.5 Analyst's Opinion Consensus RatingIradimed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIradimed has received no research coverage in the past 90 days.Read more about Iradimed's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.84% of the float of Iradimed has been sold short.Short Interest Ratio / Days to CoverIradimed has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Iradimed has recently increased by 2.44%, indicating that investor sentiment is decreasing. Previous Next 2.5 Dividend Strength Dividend YieldIradimed pays a meaningful dividend of 1.25%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthIradimed does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Iradimed is 42.55%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Iradimed will have a dividend payout ratio of 35.09% next year. This indicates that Iradimed will be able to sustain or increase its dividend.Read more about Iradimed's dividend. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIradimed has received a 67.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Real-time vital parameter monitors for MRI machines", "Intravenous therapy equipment for MRI machines", and "ECG monitors" products. See details.Environmental SustainabilityThe Environmental Impact score for Iradimed is -0.85. Previous Next 2.6 News and Social Media Coverage News SentimentIradimed has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Iradimed this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Iradimed to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Iradimed insiders have not sold or bought any company stock.Percentage Held by Insiders42.60% of the stock of Iradimed is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.34% of the stock of Iradimed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Iradimed's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Iradimed are expected to grow by 21.28% in the coming year, from $1.41 to $1.71 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Iradimed is 33.70, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 142.60.Price to Earnings Ratio vs. SectorThe P/E ratio of Iradimed is 33.70, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 155.18.Price to Book Value per Share RatioIradimed has a P/B Ratio of 8.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Iradimed's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.Click here for the full story… About Iradimed Stock (NASDAQ:IRMD)IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.Read More IRMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IRMD Stock News HeadlinesJuly 25 at 8:30 AM | globenewswire.comIRADIMED CORPORATION to Hold 2024 Second Quarter Financial Results Conference Call on August 1stJuly 18, 2024 | americanbankingnews.comIradimed Corporation (NASDAQ:IRMD) Short Interest Up 6.9% in JuneJuly 26, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” June 7, 2024 | globenewswire.comIRADIMED CORPORATION Announces Uplisting to The Nasdaq Global MarketMay 21, 2024 | finance.yahoo.comIRADIMED (NASDAQ:IRMD) Is Achieving High Returns On Its CapitalMay 6, 2024 | finance.yahoo.comIRadimed Corporation (NASDAQ:IRMD) Q1 2024 Earnings Call TranscriptMay 5, 2024 | finance.yahoo.comIRADIMED CORPORATION Just Beat EPS By 6.7%: Here's What Analysts Think Will Happen NextMay 4, 2024 | finance.yahoo.comIRADIMED First Quarter 2024 Earnings: Beats ExpectationsJuly 26, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” May 2, 2024 | finance.yahoo.comiRadimed Corp (IRMD) Reports Record Q1 Revenue, Surpasses Analyst EstimatesMay 2, 2024 | globenewswire.comIRADIMED CORPORATION Announces First Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per ShareMay 1, 2024 | msn.comiRadimed Q1 2024 Earnings PreviewApril 30, 2024 | finance.yahoo.comHere's Why We Think IRADIMED (NASDAQ:IRMD) Is Well Worth WatchingApril 25, 2024 | globenewswire.comIRADIMED CORPORATION to Hold 2024 First Quarter Financial Results Conference Call on May 2ndApril 24, 2024 | benzinga.comiRadimed Stock (NASDAQ:IRMD), Analyst Ratings, Price Targets, PredictionsApril 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Alcon (ALC) and Iradimed (IRMD)March 15, 2024 | finance.yahoo.comIRMD Jul 2024 60.000 callMarch 13, 2024 | globenewswire.comIRADIMED CORPORATION To Participate at the 36th Annual Roth ConferenceSee More Headlines Receive IRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Iradimed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Ex-Dividend for 5/30 Dividend5/17/2024Dividend Payable5/30/2024Today7/26/2024Next Earnings (Confirmed)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:IRMD CUSIPN/A CIK1325618 Webwww.iradimed.com Phone(407) 677-8022Fax407-677-5037Employees110Year FoundedN/APrice Target and Rating Average Stock Price Target$62.50 High Stock Price Target$65.00 Low Stock Price Target$60.00 Potential Upside/Downside+32.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$1.41 Trailing P/E Ratio33.57 Forward P/E Ratio33.57 P/E GrowthN/ANet Income$17.19 million Net Margins26.48% Pretax Margin33.44% Return on Equity24.63% Return on Assets20.54% Debt Debt-to-Equity RatioN/A Current Ratio9.44 Quick Ratio7.77 Sales & Book Value Annual Sales$65.56 million Price / Sales9.14 Cash Flow$1.40 per share Price / Cash Flow33.69 Book Value$5.66 per share Price / Book8.36Miscellaneous Outstanding Shares12,660,000Free Float7,269,000Market Cap$599.20 million OptionableOptionable Beta0.83 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Roger E. Susi (Age 71)Founder, Chairman, CEO & President Comp: $642.57kMr. John F. Glenn (Age 62)CFO & Corporate Secretary Comp: $541.71kMr. Randy WaddellVice President of Worldwide Sales & MarketingMr. Chris WilliamsonExecutive Vice President of Continuous Improvement & Information TechnologyMr. Matt GarnerControllerMr. Steve KachelmeyerVice President of Regulatory Affairs & Quality AssuranceMr. Lynn NeuhardtVice President of Research & DevelopmentMore ExecutivesKey CompetitorsUtah Medical ProductsNASDAQ:UTMDTELA BioNASDAQ:TELAApyx MedicalNASDAQ:APYXCo-DiagnosticsNASDAQ:CODXPolyPidNASDAQ:PYPDView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 4,363 shares on 7/26/2024Ownership: 0.458%Shaker Investments LLC OHBought 347 shares on 7/26/2024Ownership: 0.163%Allspring Global Investments Holdings LLCBought 1,570 shares on 7/26/2024Ownership: 0.139%Legato Capital Management LLCBought 1,727 shares on 7/26/2024Ownership: 0.102%Bailard Inc.Bought 4,600 shares on 7/26/2024Ownership: 0.036%View All Insider TransactionsView All Institutional Transactions IRMD Stock Analysis - Frequently Asked Questions How have IRMD shares performed this year? Iradimed's stock was trading at $47.47 at the beginning of the year. Since then, IRMD stock has increased by 0.1% and is now trading at $47.51. View the best growth stocks for 2024 here. How were Iradimed's earnings last quarter? Iradimed Corporation (NASDAQ:IRMD) released its quarterly earnings results on Thursday, May, 2nd. The medical equipment provider reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.01. The medical equipment provider earned $17.60 million during the quarter, compared to analysts' expectations of $17.26 million. Iradimed had a net margin of 26.48% and a trailing twelve-month return on equity of 24.63%. Who are Iradimed's major shareholders? Iradimed's top institutional shareholders include Liontrust Investment Partners LLP (0.51%), Bank of New York Mellon Corp (0.46%), Shaker Investments LLC OH (0.16%) and Allspring Global Investments Holdings LLC (0.14%). Insiders that own company stock include Roger E Susi, James B Hawkins, Monty K Allen, Anthony Vuoto and Christopher K Scott. View institutional ownership trends. How do I buy shares of Iradimed? Shares of IRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Iradimed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Iradimed investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Alphabet (GOOG), Mastercard (MA), Micron Technology (MU), PayPal (PYPL) and CRISPR Therapeutics (CRSP). This page (NASDAQ:IRMD) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iradimed Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Iradimed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IRMD Stock Alerts